Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries

2021 ◽  
Vol 25 (6) ◽  
pp. 50-56
Author(s):  
Michelle Delcioppo ◽  
Mary Schmitt ◽  
Joanna Bodmann ◽  
Suzanne Mahon
2021 ◽  
Vol 25 (6) ◽  
pp. 34-42
Author(s):  
Amber Whitton-Smith ◽  
Rachael Schmidt ◽  
Kristie Howlett ◽  
Rachée Hatfield ◽  
Suzanne Mahon

2021 ◽  
Vol 25 (6) ◽  
pp. 43-49
Author(s):  
Kristie Howlett ◽  
Mary Schmitt ◽  
Joanna Bodmann ◽  
Suzanne Mahon

2015 ◽  
Vol 33 (9) ◽  
pp. 1078-1085 ◽  
Author(s):  
Matthew J. Resnick ◽  
Christina Lacchetti ◽  
Jonathan Bergman ◽  
Ralph J. Hauke ◽  
Karen E. Hoffman ◽  
...  

Purpose The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components of follow-up care, including health promotion, prostate cancer surveillance, screening for new cancers, long-term and late functional effects of the disease and its treatment, psychosocial issues, and coordination of care between the survivor's primary care physician and prostate cancer specialist. Methods The American Cancer Society (ACS) Prostate Cancer Survivorship Care Guidelines were reviewed for developmental rigor by methodologists. The American Society of Clinical Oncology (ASCO) Endorsement Panel reviewed the content and recommendations, offering modifications and/or qualifying statements when deemed necessary. Results The ASCO Endorsement Panel determined that the recommendations from the 2014 ACS Prostate Cancer Survivorship Care Guidelines are clear, thorough, and relevant, despite the limited availability of high-quality evidence to support many of the recommendations. ASCO endorses the ACS Prostate Cancer Survivorship Care Guidelines, with a number of qualifying statements and modifications. Recommendations Assess information needs related to prostate cancer, prostate cancer treatment, adverse effects, and other health concerns and provide or refer survivors to appropriate resources. Measure prostate-specific antigen (PSA) level every 6 to 12 months for the first 5 years and then annually, considering more frequent evaluation in men at high risk for recurrence and in candidates for salvage therapy. Refer survivors with elevated or increasing PSA levels back to their primary treating physician for evaluation and management. Adhere to ACS guidelines for the early detection of cancer. Assess and manage physical and psychosocial effects of prostate cancer and its treatment. Annually assess for the presence of long-term or late effects of prostate cancer and its treatment.


2021 ◽  
Vol 25 (6) ◽  
pp. 57-64
Author(s):  
Michelle Delcioppo ◽  
Rachael Schmidt ◽  
Linda Goldenberg ◽  
Suzanne Mahon

2019 ◽  
Vol 8 (5) ◽  
pp. 2686-2702 ◽  
Author(s):  
Archana Radhakrishnan ◽  
Jennifer Henry ◽  
Kevin Zhu ◽  
Sarah T. Hawley ◽  
Brent K. Hollenbeck ◽  
...  

2010 ◽  
Vol 184 (2) ◽  
pp. 532-538 ◽  
Author(s):  
Ted A. Skolarus ◽  
Yun Zhang ◽  
David C. Miller ◽  
John T. Wei ◽  
Brent K. Hollenbeck

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 58-58
Author(s):  
Claire Michelle Sutherby (Bennett)

58 Background: More than 15.5 million cancer survivors live in the United States. This number is expected to be over 20 million by 2026. Cancer survivors have increased risk of morbidity; therefore, preventive and on-going medical treatment requires close monitoring and coordination. The Institute of Medicine’s (IOM) 2005 report, Cancer Patient to Cancer Survivor: Lost in Transition, recommended health providers raise awareness of cancer survivors’ needs and establish cancer survivorship as a distinct phase of care. The IOM also recommended patients who complete primary treatment are provided a comprehensive summary and plan that is effectively explained. A survivorship care plan maps out and improves care related to accessibility of past diagnosis and treatment history, surveillance guidelines, and potential long term side effects. In 2012, the Commission on Cancer (CoC) added Standard 3.3 Survivorship Care Planto the program standards. This met the IOM’s objective of addressing potential patients that get “lost” as they transition from care they received during treatment through phases of their life or disease. Methods: The Cancer Committee within a CoC certified organization developed multiple strategies to address the IOM and CoC standards. Strategies included a process to disseminate a comprehensive care summary for cancer patients who are completing primary treatment, adoption of the American Society of Clinical Oncology’s Treatment Summary and Survivorship Care Plan template, and adding a survivorship nurse navigator to the interprofessional treatment team. The survivorship nurse navigator monitors and reviews survivorship care plans with patients, advises when to seek treatment for symptoms, discusses surveillance guidelines, navigates patients through therapies, and educates on prevention and screening. Results: Evaluation for quality of life and compliance with individualized surveillance guidelines is ongoing. Conclusions: The oncology nurse navigator role is uniquely positioned to lead care coordination and improve outcomes through the continuum of care. Providing patients with a summary of their treatment and a plan moving forward may decrease stress related to the transition from active treatment to survivorship.


Sign in / Sign up

Export Citation Format

Share Document